FIELD: medicine. SUBSTANCE: method involves administering tumor necrosis factor inhibitor at a dose of 0.1 to 200 mg/kg of body mass. The tumor necrosis factor is a protein selected from tumor necrosis factor inhibitor 30 kDa, tumor necrosis factor inhibitor 40 kDa, tumor necrosis factor Δ 53 inhibitor 40 kDa or, tumor necrosis factor Δ 51 inhibitor 40 kDa. EFFECT: enhanced effectiveness in treating lung fibrosis, osteoarthritis, ankylosing spondylitis, lupus erythematosus, gonococcus-induced arthritis, Reiter disease arthritis and gout. 13 cl, 17 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COVALENT MODIFICATION OF POLYPEPTIDES WITH POLYETHYLENE GLYCOLS | 1992 |
|
RU2148586C1 |
| APPLICATION OF K-252A DERIVATIVES TO TREAT DISORDERS OF PERIPHERAL OR CENTRAL NERVOUS SYSTEMS AND EXCESSIVE CYTOKINE OUTPUT | 1997 |
|
RU2183959C2 |
| METHODS OF USING INTERLEUKIN-10 FOR TREATING DISEASES AND DISORDERS | 2014 |
|
RU2679889C2 |
| USE OF ANTIBODY FRAGMENT IN THERAPY | 1994 |
|
RU2139092C1 |
| METHODS AND APPLICATIONS OF INHIBITORS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN, TYPE 9 (PCSK9) | 2013 |
|
RU2636820C2 |
| PREPARING AND USING MONO- AND DI-PEGYLATED IL-10 | 2009 |
|
RU2549702C2 |
| URATE OXIDASE CONJUGATES, PHARMACEUTICAL COMPOSITION FOR REDUCTION IN URIC ACID LEVELS AND METHOD FOR PREPARING CONJUGATES STATED ABOVE | 2008 |
|
RU2443426C2 |
| BENZIDAMINE APPLICATION METHOD FOR TREATING PATHOLOGIC STATES INDUCED BY FUNCTIONAL METABOLISM DISORDERS | 1994 |
|
RU2160102C2 |
| TREATING OSTEOARTHRITIS AND PAIN | 2012 |
|
RU2563830C2 |
| COMBINATION THERAPY FOR TREATING HEMORRHAGIC SHOCK | 2015 |
|
RU2651778C2 |
